GlassScriptPhysician profile
Frederick J Burford
NPI 1033226329
$8,999.65
in general payments reported to CMS, 2019-2025
54 companies · $859 in 2025
The $859 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $1,135 · 2021: $1,863 · 2022: $1,620 · 2023: $1,329 · 2024: $1,443 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,066.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $819.29 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $675.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $617.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $567.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $560.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $514.97 | 2019-2022 | |
| Pfizer INC. | $492.71 | 2019-2025 | |
| Mannkind Corporation | $375.35 | 2022-2024 | Afrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $274.61 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $267.39 | 2020-2025 | Nexletol |
| Antares Pharma, INC. | $251.53 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $182.46 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $174.04 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $162.56 | 2019-2024 | Gardasil 9, Pneumovax 23, Gardasil |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Burford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.